Roth Capital Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsInitiationPrice Target
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.
Roth Capital analyst Max Masucci initiates coverage on Exagen (NASDAQ:XGN) with a Buy rating and announces Price Target of $8.